First Wave BioPharma Announces Exclusive Global License Agreement For Capeserod For Gastrointestinal Indications From Sanofi; Deal Terms Undisclosed
Portfolio Pulse from Benzinga Newsdesk
First Wave BioPharma has entered into an exclusive global license agreement with Sanofi for Capeserod, a drug for gastrointestinal indications. The terms of the deal have not been disclosed.
September 14, 2023 | 10:00 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sanofi has licensed Capeserod to First Wave BioPharma. The financial impact on Sanofi is unclear due to undisclosed deal terms.
Sanofi's licensing of Capeserod to First Wave BioPharma could potentially generate licensing revenues. However, without the terms of the deal, it's difficult to assess the exact financial impact on Sanofi.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
First Wave BioPharma has secured an exclusive global license for Capeserod from Sanofi, which could potentially boost its product portfolio and revenues.
The licensing agreement allows First Wave BioPharma to expand its product portfolio with Capeserod, which could potentially lead to increased revenues. However, the undisclosed terms of the deal make it difficult to fully assess the financial impact.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100